


## Azide-PEG9-amido-C12-Boc

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-140790   |
| Molecular Formula: | C <sub>38</sub> H <sub>74</sub> N <sub>4</sub> O <sub>12</sub>                            |
| Molecular Weight:  | 779.01  |
| Target:            | PROTAC Linkers  |
| Pathway:           | PROTAC  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

|                                     |   |             |
|-------------------------------------|---|-------------|
| <b>Description</b>                  | Azide-PEG9-amido-C12-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . Azide-PEG9-amido-C12-Boc is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups. |             |
| <b>IC<sub>50</sub> &amp; Target</b> | PEGs  | Alkyl/ether |
| <b>In Vitro</b>                     | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |             |

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA